Brief Report: Prospective Trial of Pembrolizumab Monotherapy in Metastatic NSCLC Evaluating Circulating Tumor DNA as a Surrogate Biomarker of Response by Iris van 't Erve, PhD, Isabelle Blanchard, BS, Judy Y. Pagtama, MSN, Alison J. Holmes Tisch, MSN, Ash A. Alizadeh, MD, PhD, Kavitha Ramchandran, MD, Heather A. Wakelee, MD, Sukhmani K. Padda, MD, Maximilian Diehn, MD, PhD, Joel W. Neal, MD, PhD

Get full text

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial by Paolo Strati, Lei Feng, Jason R. Westin, Ranjit Nair, Luis E. Fayad, Maria A. Rodriguez, Dai Chihara, Luis Malpica, Jared Henderson, Mariana Gallardo, Marissa Rivera, Iris Wang, Anastasiia Bolshakova, Anastasia Radko, David Kurtz, Stefan K. Alig, Christopher R. Flowers, Ash A. Alizadeh, Sattva S. Neelapu

Get full text

IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies by Pablo Domizi, Jolanda Sarno, Astraea Jager, Milton Merchant, Kaithlen Zen B. Pacheco, Sean A. Yamada-Hunter, Maria Caterina Rotiroti, Yuxuan Liu, Reema Baskar, Warren D. Reynolds, Brian J. Sworder, Bita Sahaf, Sean C. Bendall, Charles G. Mullighan, Ash A. Alizadeh, Allison B. Leahy, Regina M. Myers, Bonnie Yates, Hao-Wei Wang, Nirali N. Shah, Robbie G. Majzner, Crystal L. Mackall, Stephan A. Grupp, David M. Barrett, Elena Sotillo, Kara L. Davis

Get full text